Current Report Filing (8-k)
March 29 2023 - 7:46AM
Edgar (US Regulatory)
0001739174
false
0001739174
2023-03-29
2023-03-29
0001739174
PHGE:UnitsEachConsistingOfOneShareOfCommonStock0.0001ParValueAndOneWarrantEntitlingHolderToReceiveOneHalfShareOfCommonStockMember
2023-03-29
2023-03-29
0001739174
PHGE:SharesOfCommonStock0.0001ParValueMember
2023-03-29
2023-03-29
0001739174
PHGE:WarrantsEachExercisableForOnehalfOfShareOfCommonStock0.0001ParValueAtExercisePriceOf11.50PerShareMember
2023-03-29
2023-03-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 29, 2023
BiomX Inc. |
(Exact Name of Registrant as Specified in its Charter) |
Delaware |
|
001-38762 |
|
82-3364020 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
22 Einstein St., Floor 4
Ness Ziona, Israel |
|
7414003 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: +972 723942377
n/a |
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name
of each exchange on which registered |
Units, each consisting of one share of Common Stock, $0.0001 par value, and one Warrant entitling the holder to receive one half share of Common Stock |
|
PHGE.U |
|
NYSE American |
Shares of Common Stock, $0.0001 par value |
|
PHGE |
|
NYSE American |
Warrants, each exercisable for one-half of a share of common stock, $0.0001 par value, at an exercise price of $11.50 per share |
|
PHGE.WS |
|
NYSE American |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On March 29, 2023, BiomX Inc. (the “Company”) issued a
press release announcing its financial results for the fourth quarter ended December 31, 2022. A copy of the press release issued in connection
with the announcement is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.
Item 5.08 Shareholder Director Nominations.
On March 28, 2023, the
Board of Directors of the Company established that the Company’s 2023 Annual Meeting of Stockholders (the “Annual Meeting”)
will be held on Tuesday, June 20, 2023 and has fixed the closing of business on April 27, 2023 as the record date for the Annual Meeting.
Because the date of the Annual Meeting has been changed by more than 30 days from the anniversary date of the 2022 Annual Meeting of Stockholders,
which was held on August 24, 2022, the deadlines for any stockholder proposals pursuant to Rule 14a-8 under the Securities Exchange Act
of 1934, as amended (the “Exchange Act”) and for any stockholder nomination or proposal outside of Rule 14a-8, as listed in
the Company’s 2022 Proxy Statement on Schedule 14A, as filed with the Securities and Exchange Commission (the “SEC”)
on July 7, 2022, are no longer applicable.
In
accordance with Rule 14a-5(f) and Rule 14a-8(e) under the Exchange Act, the deadline for receipt of stockholder proposals for inclusion
in the Company’s proxy statement for the Annual Meeting pursuant to Rule 14a-8 will be no later than 5:00 p.m., Eastern Time, April
17, 2023. Stockholder proposals must comply with all of the applicable requirements set forth in the rules and regulations of the Securities
and Exchange Commission, including Rule 14a-8 under the Exchange Act and the Company’s Bylaws.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIOMX INC. |
|
|
|
March 29, 2023 |
By: |
/s/ Jonathan Solomon |
|
|
Name: |
Jonathan Solomon |
|
|
Title: |
Chief Executive Officer |
2
BiomX (AMEX:PHGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiomX (AMEX:PHGE)
Historical Stock Chart
From Apr 2023 to Apr 2024